Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eribulin plus Bevacizumab in 2nd-line HER2-negative MBC (BERGI)
NCT02175446Phase 2Unknown
- Sponsor
- Consorzio Oncotech
- Start
- Sep 2014
- Primary completion
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of eribulin in breast cancer, sponsored by Consorzio Oncotech. Status: unknown.
02
Drugs
eribulin
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02175446.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02175446.